Stockreport

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease [Yahoo! Finance]

Quanterix Corporation  (QTRX) 
US:NASDAQ Investor Relations: ir.quanterix.com/investor-relations
PDF high-definition diagnostics, announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food an [Read more]